Last updated: 13 May, 2026

Like all medications, Novo Nordisk’s Wegovy comes with a risk of side effects. Not everyone will experience them (most tolerate the medication well) but 1 in 10 patients do get common side effects, like nausea, headaches and constipation.

And if you’re on the 2.4 mg dose and looking to increase to 7.2 mg, you might be worried side effects will get worse.

Find out more about Wegovy 7.2 mg side effects, how they compare to lower doses of the medication, the effect of the Wegovy dosage titration process on side effects, and when you should seek medical advice.

Understanding Wegovy 7.2 mg

The 7.2mg dose of Wegovy injections is taken in exactly the same way as all the other doses – self-administered once per week.

The pen format is changing to a single-use 7.2mg pen (previously 3x 2.4 mg pens), meaning the full weekly dose is now delivered in one injection.

It contains the same active ingredient, semaglutide, and was developed specfically to provide adults living with obesity achieve suffcient results after sustained plateaue on the standard 2.4 mg maintenance dose.

Common Wegovy Side Effects

If you’ve been taking Wegovy at a lower dose, you’ll probably already be familiar with the most common side effects of this medication. The Patient Information Leaflet (PIL) lists the following:

  • Nausea
  • Diarrhoea
  • Vomiting
  • Constipation
  • Stomach pain
  • Headache
  • Fatigue
  • Dizziness
  • Bloating
  • Belching
  • Gas
  • Stomach flu
  • Heartburn
  • Low blood sugar in people with type 2 diabetes

As common side effects, these have typically been reported by at least 1 in 10 people taking the medication. They are usually mild, and most people find that they get easier to manage as their body becomes used to their new medication.

There are also things that you can do to help you better manage your side effects, so they don’t become too disruptive to your day-to-day life.

Are Side Effects Worse at Wegovy 7.2 mg?

Wegovy 7.2 mg is simply a higher dose of the medication that contains the same active ingredient. So reported side effects are similar to those seen in people taking lower Wegovy doses.

This means that they too are mainly gastrointestinal. The most common ones include nausea, changes in bowel habits such as diarrhoea and constipation, vomiting and abdominal pain.

And just like lower doses, studies report that, for most people, these side effects are mild to moderate. They also get better and become easier to manage the longer they take the 7.2 mg dose.

In addition to the most common side effects of Wegovy, clinical trials found patients reported an increase in dysesthesia. This is a condition where you feel abnormal or uncomfortable sensory feelings like burning, tingling, electric shock-type sensations. It can affect any part of the body.

The Effect of Titration on Wegovy Side Effects

When you start taking Wegovy, you’ll start on the lowest dose. The side effects from taking Wegovy usually lessen or disappear completely when your body gets used to the medication.

However, most people don’t stick at the 0.25 mg dose. Instead, they follow the titration process, working up through different doses to find the one that works best for their weight loss goals. This means that you may experience a temporary return of or increase in your side effects each time you titrate up to the next dose.

It’s important that you don’t skip the titration process, which involves increasing the weekly dose every four weeks until you reach your optimal maintenance dose.

This is because titrating gives your body a chance to get used to the side effects and makes it easier to stick with the treatment long-term.

When to Seek Medical Help for Side Effects

Although most people only experience mild side effects from taking Wegovy, it can potentially cause much more serious side effects that require urgent medical attention. You should speak to your doctor or another licensed healthcare provider right away if you experience any of the following:

  • Severe abdominal pain that doesn’t go away, with or without nausea and vomiting
  • Pain in your upper stomach, fever, yellowing skin or eyes, or clay-coloured bowel movements
  • Signs of low blood sugar (hypoglycaemia) including dizziness, blurred vision, slurred speech, heart palpitations and more
  • Ongoing vomiting or diarrhoea that doesn’t stop
  • Signs of an allergic reaction, such as swelling of your face, lips and tongue, breathing difficulties, severe rash etc
  • Changes in your vision
  • Heart palpitations
  • Severe mood changes 

If you would like more information about the side effects associated with Wegovy 7.2 mg, please don’t hesitate to speak to our experienced and knowledgeable clinical team.

References

Sean Wharton, MD, Paula Freitas, PhD, Jøran Hjelmesæth, MD, Maria Kabisch, PHD, Kristian Kandler, MD, Prof Ildiko Lingvay, MD, et al. 2025. The Lancet, Volume 13, Issue 11. Once-weekly semaglutide 7.2mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Available from: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00226-8/abstract.

Wegovy. 2026. Online. What might you expect with Wegovy? Available from: https://www.wegovy.com/obesity/is-wegovy-right-for-me/safety-side-effects.html [Accessed Feb 2026].

National Institute for Health and Care Excellence. 2026. Online. Adverse reactions to drugs. Available from: https://bnf.nice.org.uk/medicines-guidance/adverse-reactions-to-drugs/ [Accessed February 2026].

Gurdeep Singh, Matthew Krauthamer, Meghan Bjalme-Evans. 2021. Wegovy (Semaglutide): a new weight loss drug for chronic weight management. PMID: 34706925. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8717485/.

John P.H. Wilding, Rachel L Batterham, Salvatore Calanna, Melania Davies, Luc F. Van Gaal, Ildiko Lingvay, Barbara M. McGowan, et al. 2021. The New England Journal of Medicine. Once-Weekly Semaglutide in Adults with Overweight or Obesity. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183 [Accessed February 2026].

European Medicines Agency. 2026. Online. Product Information: Wegovy (semaglutide). Available from: https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf. [Accessed February 2026].

Wegovy. 2026. Online. Your Complete Guide to Wegovy Pen. Available from: https://www.wegovy.com/obesity/starting-wegovy/starting-wegovy-pen.html [Accessed Feb 2026].

Jason M. Samuels MD, Fei Ye PhD, Rebecca Irlmeier MS, Heidi Silver RD, Gitanjali Srivastava MD, Matthew Spann MD. 2025. Diabetes, Obesity and Metabolism. Real-world titration, persistence and weight loss of semaglutide and tirzepatide in an academic obesity clinic. Available from: https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.70004 [Accessed Feb 2026].

Authorship

Dee Primett author

Authored by Dee Primett

Content Writer

Dee Primett is a content writer at Simple Online Pharmacy. She’s spent the last 11 years helping leading UK and global health and medtech brands to connect with their audience through clear, engaging and accessible content. She’s passionate about health advocacy, using her own experiences of cancer and autoimmune diseases to raise awareness and empower others to take control of their health and wellbeing.

Richard Wood, Pharmacist

Medically Reviewed by Richard Wood

Pharmacist / Clinical Specialist
GPhC reg: 2078802
Richard is a pharmacist and content reviewer at Simple Online Pharmacy. He officially joined the team in 2024 after several years of working with the company as a contractor. Prior to that, he spent over 11 years as a community pharmacist, building a strong foundation in patient care.

Was this article helpful?
YesNo